Vendors
Tamarind Bio Selected for Eli Lilly's AI Drug Discovery Platform, TuneLab 2.0
Eli Lilly and Company has selected Tamarind Bio to build, host, and operate the inference infrastructure for TuneLab 2.0, the next version of its drug discovery platform. The selection was noted in a June 10, 2026 announcement from Y Combinator.
By The Desk - Jordan Leahy·June 11, 2026
Tamarind Bio will be responsible for the platform's inference layer and will power its scalable drug discovery workflows and model inference.
Eli Lilly's TuneLab is an artificial intelligence and machine learning platform for collaborative drug discovery. According to the announcement, it uses models trained on over $1 billion worth of proprietary Lilly data, which it makes available to the biotech ecosystem.